Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Case Report

Volume 11, Number 4, August 2022, pages 154-158


Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin

Figure

Figure 1.
Figure 1. (a-c) The large neck lymph nodes involved by Hodgkin lymphoma and the dramatic response to the combination of an immune checkpoint inhibitor with brentuximab vedotin. (d, e) Endomyocardial biopsy findings by light (d) and electron (e) microscopy. (d) The myocardium is free of active inflammatory infiltrates but exhibits evidence of previous myocardial insult represented by a focus of replacement fibrosis (RF, white asterisk) (1-µm section stained with toluidine blue, × 500). (e) Some areas of myocardium had increased interstitial collagen with an occasional macrophage but no aggregates of inflammatory cells between the cardiomyocytes (× 2,000).